non- alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: 3 caposouls of CLA(each containing 1000mg, daily 3000mg) with weight loss diet for eight weeks in intervention group. Intervention 2: weight loss diet for eight weks in control group.
Treatment - Drugs
Treatment - Other
3 caposouls of CLA(each containing 1000mg, daily 3000mg) with weight loss diet for eight weeks in intervention group
weight loss diet for eight weks in control group
Sponsors
Deputy of research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Verification of having NAFLD (based on liver ultrasound and liver enzyme levels above normal values ??based on kits used); 20-50 years old; BMI=30-40; takeing 400IU vitamin E daily. Exclusion criteria: Consumption of alcohol; Pregnancy or lactation and menopause; being athleteic; Inflammatory conditions such as infection; history or perceive of hypertension; Family history of hyperlipidemia; history or perceive of cardiovascular disease; history or perceive of lung disease; history or perceive of renal disease; Liver transplantation; Acute or chronic disorders and other diseases of the liver (hepatitis B, C and liver infections, etc.); Biliary disease; Known Autoimmune disease; Cancer; An inherited disorder affecting the liver status (iron and copper storage disease, etc.); Perceive diseases such as burns and injury during the study; surgery in last 3 months; the use of some medications such as antihypertensitives, insulin sensitivity enhancer, hepatotoxic drugs , statines; Taking any vitamins, minerals and antioxidant supplementation in the last two months; Taking contraceptive pills and estrogen; Consumption of flaxseed; consumption of nuts more than 3 per day .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resistin. Timepoint: Beginning and end of the intervention. Method of measurement: Elisa.;Inflammatory factors(IL-6,Il-10,TNFa,hs-CRP). Timepoint: Begining and end of the study. Method of measurement: IL-6,Il-10,TNFa: Elisa and hs-CRP : immunoturbidimetry.;Insulin resistance and Insulin sensitivity. Timepoint: Beginning and end of the intervention. Method of measurement: Insulin resistance with HOMA-IR index and Insulin sensitivity with Quicki index.;Liver enzymes(AST-ALT-ALP). Timepoint: Beginning and end of the intervention. Method of measurement: IFCC.;Lipid profile. Timepoint: Beginning and end of the intervention. Method of measurement: Spectrophotometry and Friedewald Formula for LDL.;Oxidative Stress Indicies(TAC-ARE-MDA). Timepoint: Beginning and end of the intervention. Method of measurement: TAC and ARE : spectrophotometry and MDA : thiobarbituric acid.;?Sonography faindings. Timepoint: Beginning and end of the intervention. Method of measurement: Liver Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometry(BMI-WC-WHR-WHtR). Timepoint: Beginning, second, fourth, sixth and end of the intervention. Method of measurement: metr, scale and stadiometr.;Body composition. Timepoint: Beginning and end of the intervention. Method of measurement: BIA.;Energy and nutrient intake. Timepoint: beginning, fourth week and end of the intervention. Method of measurement: 3 day food record.;Comparison of physical activity. Timepoint: beginning, fourth week and end of the intervention. Method of measurement: Physical Activity Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehrangiz Ebrahimimamagani
Deputy of Research, Nutrition faculty, Tabriz University of Medical Sciences
Outcome results
None listed